Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

Inclusion Criteria: * male or female, 7 to 17 year old (inclusive) at the time of signing consent * meets DSM-IV-TR diagnostic criteria for Tourette's Disorder * Presenting tic symptoms cause impairment in the subject's normal routines, which include academic achievement, occupational functioning, social activities, and/or relationships * Females of childbearing potential must have a negative pregnancy test, must be practicing acceptable double-barrier methods of contraception and must not be pregnant or lactating * Written informed consent obtained from a legally acceptable representative \& informed assent at Screening as applicable by trial center's IRB/IEC * The subject, designated guardian(s) or caregiver(s) are able to comprehend and satisfactorily comply with the protocol requirements, as evaluated by the investigator Exclusion Criteria: * Clinical presentation and/or history, consistent with another neurologic condition that may have accompanying abnormal movements * History of schizophrenia, bipolar disorder, or other psychotic disorder * Subject receiving psychostimulants for treatment of ADD/ADHD and who have developed and/or had exacerbations of tic disorder after initiation of stimulant treatment * Currently meets DSM-IV-TR criteria for a primary mood disorder * Severe Obsessive Compulsive Disorder (OCD) * Taken aripiprazole within 30 days of the Screening visit * Received any investigational agent in a clinical trial within 30 days prior to Screening, enrolled in studies 31-12-272, 31-12-273, 31-12-274; or who were randomized into a clinical trial with Once-daily aripiprazole at any time * History of neuroleptic malignant syndrome * Sexually active patients not using 2 approved methods of contraception * Females breastfeeding or pregnant (positive blood pregnancy test prior to receiving trial drug) * Risk of committing suicide * Body weight lower than 16 kg * Taken neuroleptic or antiparkinson drugs \< 14 days prior to randomization * Requiring cognitive behavioral therapy (CBT) for Tourette's during trial * Subject meets DSM-IV-TR criteria for any significant psychoactive substance use disorder within the past 3 months * Positive drug screen * Subject requires medications not allowed per protocol * Use of CYP2D6 and CYP3A4 inhibitors or CYP3A4 inducers within 14 days prior to dosing and for duration of trial * Use of herbal medications of any kind and nutritional or dietary supplements for Tourette's disorder within 7 days prior to dosing and for the duration of the trial * Inability to swallow tablets or tolerate oral medication * Abnormal laboratory test results, vital signs and ECG results